Compare VINP & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | CRMD |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 590.7M |
| IPO Year | 2020 | 2009 |
| Metric | VINP | CRMD |
|---|---|---|
| Price | $9.31 | $7.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $14.00 | ★ $14.83 |
| AVG Volume (30 Days) | 41.3K | ★ 763.1K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $18.07 | $0.30 |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $24.41 | ★ $10.67 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $9.13 | $6.13 |
| 52 Week High | $13.61 | $13.02 |
| Indicator | VINP | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 41.68 |
| Support Level | N/A | $7.09 |
| Resistance Level | $10.21 | $9.01 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 14.94 | 8.12 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.